Healthcare / BiotechnologyNasdaqGS
$12.67
-0.49 (-3.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-96.7M · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$368M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-126.5%
↓Gross Margin
N/A
•Debt/Equity
0.89
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+3.2%
FCF CAGR
—
FCF margin
-49.2%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65.3M · net income $-81.9M · FCF $-32.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $65.3M | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M | $160.9M | $47.7M | $32.1M | $41.7M | $41.9M |
| Net Income | $-81.9M | $-81.9M | $-116.0M | $-133.8M | $-121.8M | $-79.0M | $-36.2M | $46.4M | $72.0M | $17.7M | $21.7M | $79.0M | $34.4M | $9.6M | $21.4M | $23.3M |
| EBITDA | $-71.3M | $-71.3M | $-104.5M | $-123.5M | $-119.2M | $-106.2M | $-38.0M | $40.0M | $90.8M | $26.8M | $32.5M | $124.8M | $19.3M | $9.3M | $21.5M | $25.8M |
| EPS | -3.84 | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 | 1.13 | 1.32 |
| Operating Margin | -130.7% | -130.7% | -179.9% | -173.2% | -143.7% | -112.9% | -34.0% | 17.9% | 42.7% | 23.9% | 34.9% | 77.2% | 39.8% | 28.2% | 51.0% | 60.4% |
| Net Margin | -125.4% | -125.4% | -171.6% | -169.0% | -141.3% | -81.4% | -29.5% | 22.6% | 34.8% | 17.2% | 24.5% | 49.1% | 72.1% | 30.0% | 51.3% | 55.7% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.89 | 0.89 | 0.43 | 0.12 | 0.08 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 3.84 | 3.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-32.2M | $-32.2M | $-96.7M | $-112.2M | $-86.9M | $-70.7M | $5.6M | $66.0M | $26.2M | $50.1M | $31.1M | — | — | $10.0M | $22.4M | $23.6M |
| Returns | ||||||||||||||||
| ROE | -126.5% | -126.5% | -90.1% | -61.7% | -37.9% | -19.8% | -7.9% | 10.0% | 18.3% | 5.9% | 8.0% | 33.4% | 23.2% | 8.7% | -18.6% | -17.7% |
| Valuation | ||||||||||||||||
| P/B | 4.18 | 4.18 | 1.87 | 0.95 | 3.10 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -3.4% | -3.4% | -14.6% | -8.1% | — | -20.7% | -40.3% | -0.7% | 101.0% | 16.5% | -45.1% | 237.0% | 48.9% | -23.1% | -0.4% | — |
| EPS Growth | 29.9% | 29.9% | 14.1% | -8.0% | — | -116.6% | -181.9% | -36.5% | 282.4% | -19.5% | -72.4% | 127.2% | 368.7% | -159.3% | -14.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+113.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.48 → -3.84
Residual
+113.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.